Contact a Rep
CONTACT A REP
Interested in connecting with an ANI Pharmaceuticals representative?

Fill out the request form below if you wish to be contacted with more information on Cortrophin Gel.

This form is for healthcare professionals only. If you are a patient looking to contact customer service, please call 1-800-434-1121 or email info@anipharmaceuticals.com.

* = Required

I confirm and agree to the following:*

I am a licensed US healthcare professional. I understand that this information may be used by ANI Pharmaceuticals and its affiliates and partners or third parties working on behalf of ANI Pharmaceuticals to contact me. I agree that the personal information I provide may be used by ANI Pharmaceuticals, or other companies acting on its behalf, to contact me via mail, email, or otherwise provide me with information about educational materials, market research, products, and services concerning Cortrophin Gel. I give my permission for ANI Pharmaceuticals to use my information for reasonable business purposes as permitted or required by law. Neither ANI Pharmaceuticals nor the companies working on its behalf may sell or rent my personal information except for as set forth in the ANI Pharmaceuticals Privacy Policy.

* = Required

Prescribe Cortrophin Gel today!

Here’s how you can get your patients started with Cortrophin Gel:

vials
5 mL1 mL

For intramuscular or subcutaneous use.

Vial sizes are
not to scale.

syringes1 mL0.5 mL

For subcutaneous
use only.

Prefilled syringe sizes are
not to scale.

To begin the prescription process, complete and sign the Enrollment Form with your patient.

  • The Enrollment Form includes prescription information and also serves as enrollment into the Cortrophin In Your Corner (CIYC) support program*

DOWNLOAD ENROLLMENT FORM

*Not all patients will be eligible for all services offered by Cortrophin In Your Corner.

  • 5-mL vial & Prefilled Syringes: Fax the completed form and copies of all insurance and prescription cards to 1-844-FAX-CIYC (1-844-329-2492)
  • 1-mL vial: Fax the completed form and copies of all insurance and prescription cards to 1-833-468-8352
  • Podiatry and Primary Care: Fax the completed form and copies of all insurance and prescription cards to 1-844-FLARE-NOW (1-844-352-7366)

After you submit the Enrollment Form, Cortrophin In Your Corner will conduct the benefits investigation and fax the Summary of Benefits to your office. Cortrophin In Your Corner or your company representative can help with the prior authorization process if one is required.

  • An ANI Nurse Access Specialist (NAS) will conduct a welcome call with your patient, while the specialty pharmacy will determine if Cortrophin Gel is covered by your patient's insurance
  • The NAS will be your patient's point of contact and help them navigate the treatment process†
  • Commercially insured patients may be eligible for cost savings through Cortrophin In Your Corner.* Once the medication is approved, please have your patient call their NAS at 1-800-805-5258 to discuss financial options, including copay assistance programs

*Not all patients will be eligible for all services offered by Cortrophin In Your Corner.

†Nurse Access Specialists do not give medical advice and will direct patients to their healthcare professional for any treatment-related questions.

Download the appropriate Enrollment Form to begin the prescription process:

Download the appropriate Enrollment Form based on the desired vial size to begin the prescription process:

Checklist icon

Enrollment Form for Podiatry
and Primary Care

English
SpanishCOMING SOON
Checklist icon

1 mL Vial Enrollment Form

English
Spanish
Checklist icon

5 mL Vial & Prefilled Syringes
Enrollment Form

English
Spanish
Checklist icon

5 mL Vial & Prefilled Syringes Enrollment
Form for Severe Inflammatory
Ophthalmic Diseases

English

Cortrophin Gel is also available for in-office administration.

View in-office resources

Visit our resource library to view all Cortrophin Gel resource materials:

Explore Resources
Cortrophin In Your Corner Logo

Learn more about the Cortrophin In Your Corner (CIYC) patient support program

With CIYC, eligible commercially-insured patients may pay as little as $0 per prescription fill for Cortrophin Gel, if receiving through a pharmacy.‡

‡Restrictions, limitations, and/or eligibility requirements apply. The maximum financial assistance provided to eligible patients is $25,000 per calendar year. The patient will be responsible for any remaining out-of-pocket costs for Cortrophin Gel for that calendar year.

LEARN MORE
See full Terms & Conditions
Flashcard icon
Cortrophin Gel is available at select specialty pharmacies

To see a list of the specialty pharmacies that are authorized to carry Cortrophin Gel,
download the procurement flashcards.

Procurement
Flashcard

Download Flashcard

Podiatry and Primary Care Procurement Flashcard

Download Flashcard
Proposed Mechanism
of Action

Discover how ACTH may work by viewing its proposed mechanism of action (MOA).

Learn More
About Cortrophin Gel & Dosing

Learn more about Cortrophin Gel and view recommended dosing by indication.

Learn about dosing
Patient Support & Reimbursement

See how Cortrophin In Your Corner, our dedicated patient support program, can help patients throughout the treatment process.

EXPLORE SUPPORT
Indications
Important Safety Information
Expand ISI
IndicationsExpand ISI

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationExpand ISI
Contraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.

Indications

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationContraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.